Previous reports suggest that TLR1/2 agonist BLP (bacterial lipoprotein) can effectively inhibit lung cancer, leukemia and melanoma development, leading to a long‐lasting protective response against tumor rechallenge.11 Moreover, TLR1/2's agonist PSK has shown significant effects in the inhibition of both implanted and spontaneous breast tumors and is already in phase II clinical trial.2 However, in vivo antitumor activity of TLR1/2 small molecule agonists has rarely been reported. This evidence concerns the gene TLR1 and melanoma.